Episcleral Dexamethasone for Macular Edema

Recruiting in Palo Alto (17 mi)

Overseen byTheodore Leng, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Targeted Therapy Technologies, LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

Research Team

Theodore Leng, MD

Principal Investigator

Stanford Medicine

Eligibility Criteria

This trial is for adults over 18 with certain eye conditions like macular edema, retinal diseases, and inflammation of the retina or vitreous. Participants must have a specific range of visual acuity (roughly between 20/32 to 20/320 vision) and show signs of swelling in the central part of their retina.

Inclusion Criteria

I have inflammation in parts of my eye.

Your eye doctor sees swelling in the central part of your retina.

I am 18 years old or older.

See 1 more

Treatment Details

Interventions

Episcleral Dexamethasone (Corticosteroid)

Trial OverviewThe trial is testing Episcleral Dexamethasone's safety and its ability to reduce inflammation in patients with macular edema or other inflammatory disorders affecting the back part of the eye.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Phase I open label studyExperimental Treatment1 Intervention

Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone Other Names: • Sustained Release Transscleral Dexamethasone